English

CS MEDICA A/S Interim Report Q4 (July - September 2025)

Report this content

CS MEDICA A/S (“CS MEDICA”) reports its Q4 results for July–September 2025, showing increased revenue, an improved gross margin, and strengthened commercial activity, while the Company continued disciplined cost control and progressed its MDR transition.

Financial Performance (Q4 2024/2025)

  • Revenue: DKK 2.3 million (Q4 2023/2024: DKK 3.5 million), driven entirely by EU partners through new onboarding and repeat orders.

  • Gross profit: DKK 1.28 million (2024/2025), up from DKK 1.08 million last year — lifting the gross margin to 55% (from 31%).

  • Operating result (EBIT): DKK –2.24 million, an improvement from –2.84 million last year.

  • Order intake: DKK 3.7 million, supported by a new German partner preparing a 100,000-unit launch upon MDR completion.

  • Commercial pipeline: DKK 21.7 million, with DKK 8 million already in translations, artwork, production, release, or MDR transition.

  • Operating cash flow: DKK +0.96 million, compared to –5.07 million in Q4 last year.

Operational & Regulatory Progress
The Company completed its third on-site BSI audit, continued technical and biological file handling, and maintained full ISO 13485 and MDR-aligned QMS compliance. International regulatory progress advanced in Jordan, China’s Hainan Pilot Zone, and Thailand.

Outlook
With improved quarterly profitability, a strengthened pipeline, and rising EU-driven revenue, CS MEDICA enters FY 2025/2026 with increased commercial momentum and a stronger operational foundation. Financial planning continues to target cash-positive and EBITDA-positive performance in the coming financial year.

Picture Q4.png

For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/
 

CS MEDICA A/S, a Danish MedTech pioneer, specializes in developing evidence-based, over-the-counter treatments infused with CBD for pain management, autoimmune and stress-related disorders. With a focus on patient-centric care, our products range from innovative R&D to registered, regulated, non-prescription-based medical devices and dermaceuticals. Our flagship CANNASEN® brand, alongside our own-label solutions, exemplifies our dedication to safe, high-quality treatments for both human and veterinary health globally. For more information, visit cs-medica.com and LinkedIn.

Tags:

Q4Report CS MEDICA cannabisindustri 20242025

Subscribe

Documents & Links